Form D · Other Health Care
Salish Bioscience Inc.
Seattle, WA · CIK 0001922451
Offering snapshot reported Apr 14, 2022 · SEC filing
- Reported sold
- $7.04M Offering amount: $7.04M
- Investors reported
- 25 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 31, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 14, 2022 | Initial | $7,037,397 | No comparison | 25 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-441884
Total amount sold is comprised of a cash amount equal to $6,000,000 plus $1,037,397 upon conversion of existing convertible notes.
Series Seed Preferred Stock and conversion of notes
Source: Form D, filed Apr 14, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kira Misura | Director |
| Frank Paganelli | Director, Executive |
| Chris Raymond | Director |
| Fenella Raymond | Director, Executive |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
3005 1st Avenue Suite 204
Seattle, WA, 98121
Seattle, WA, 98121